IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials.
The podcast, hosted by Vial EVP, Rich McCormick, is available for on-demand listening on First in Human by Vial.
During the interview, Etherington highlighted information about Clene’s work in the field of nanotechnology.
“For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my brain. We had the idea to do that with a catalytically active nanotherapeutic suspension, which the patients drink daily.”
“We first completed some translational medicine work, whereby we were able to show that our drug taken orally got into the stomach then into the bloodstream and then across the blood brain barrier to drive the key bio energetic metabolites that you and I rely upon for energy… we were able to reverse the clock potentially by decades, in terms of key bioenergetic metabolites. We then proceeded into two amyotrophic lateral sclerosis (ALS) studies and one multiple sclerosis study, all of which have concluded in the past 18 months. These studies have shown the ability (of CNM-Au8®) to improve function, which can be translated as how to improve the way patients move and walk and talk and eat and chew and breathe.”
Throughout the interview, Etherington continued to detail Clene’s efforts in nanotechnology, discussing how this approach differentiates the company’s pipeline from traditional treatment options.
Learn more by listening to the full episode on First in Human by Vial.
About IBN
IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.